SPONSOR
BioNTech SE
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2, Phase 1, Phase 2
Conditions studied: Advanced Solid CancersNon-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma (PDAC)
BioNTech SE is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Advanced Solid Cancers, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (PDAC).
The trial portfolio spans Phase 1, Phase 2, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — BioNTech SE
How many clinical trials has BioNTech SE sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by BioNTech SE, of which 3 are actively recruiting participants. These trials cover conditions including Advanced Solid Cancers, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (PDAC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does BioNTech SE research focus on?
BioNTech SE clinical trials span Advanced Solid Cancers, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (PDAC). The research pipeline includes Phase 1, Phase 2, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a BioNTech SE clinical trial?
To participate in a BioNTech SE trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all BioNTech SE trials with current recruitment status updated daily.
Clinical Trials by BioNTech SE
NCT07186842 Phase 1, Phase 2
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Advanced Solid Cancers
NCT05142189 Phase 1
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
NCT07255404 Phase 2
Recruiting
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology